中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 6
Jun.  2018
Turn off MathJax
Article Contents

Clinical features of IgG4-associated sclerosing cholangitis: An analysis of 12 cases

DOI: 10.3969/j.issn.1001-5256.2018.06.024
  • Received Date: 2017-11-20
  • Published Date: 2018-06-20
  • Objective To investigate the clinical features, steroid response, and recurrence of Ig G4-associated sclerosing cholangitis (Ig G4-SC) , and to shorten the time for clinical diagnosis and reduce recurrence rate. Methods A total of 12 patients with Ig G4-SC who were admitted to Peking University First Hospital from December 2011 to March 2017 were enrolled, and they all met the clinical diagnostic criteria for Ig G4-SC in 2012. A retrospective analysis was performed for their clinical data, clinical features, and follow-up data. Results Of all 12 patients, the male/female ratio was 11∶ 1. The mean age of onset was 61. 7 ± 8. 6 years, and the mean time to a confirmed diagnosis was 24. 2 months. Of all 12 patients, 11 (92%) had jaundice, with a mean serum total bilirubin level of 198. 7 ± 57. 7 μmol/L. There were varying degrees of increase in serum alanine aminotransferase level (range 55-453 U/L) . Of all patients, 5 (41. 7%) had acute abdominal pain, with a mean CA19-9 level of 60. 8 ± 12. 5 U/ml. Serum Ig G4 was increased by 1. 5-18. 9 times, with a mean level of 7. 7 ± 2. 0 g/L. Magnetic resonance cholangiopancreatography (MRCP) performed for all patients showed typical manifestations including bile duct wall thickening, lumen stenosis, and intrahepatic and extrahepatic bile duct dilatation; 11 patients (92%) were found to have autoimmune pancreatitis, and 2 (16. 7%) had involvement of more than 3 visceral organs. In two patients who underwent biliary stent implantation before treatment, the biliary stent was removed after 4-6 weeks of steroid treatment. The mean duration of steroid response was 5. 4 months. Among the 8 patients who underwent steroid treatment, 4 (50%, 4/8) experienced recurrence during the reduction of the dose of steroid, among whom 2 experienced recurrence within 8-12 weeks after drug withdrawal. Conclusion Ig G4-SC needs a long time for prognosis, with frequent misdiagnosis and missed diagnosis. Serum Ig G4 level should be measured for elderly male patients with an acute onset of jaundice and bile duct stenosis, bile duct wall thickening, and involvement of the pancreas on MRCP. Steroid treatment should be given as early as possible after diagnosis. Patients may need at least 5-6 months to achieve steroid response. The dose of steroid should be reduced slowly and recurrence and tumorigenesis should be closely monitored.

     

  • loading
  • [1]BRITO-ZERON P, RAMOS-CASALS M, BOSCH X, et al.The clinical spectrum of Ig G4-related disease[J].Autoimmun Rev, 2014, 13 (12) :1203-1210.
    [2]CULVER EL, CHAPMAN RW.Ig G4-related hepatobiliary disease:an overview[J].Nat Rev Gastroenterol Hepatol, 2016, 13 (10) :601-612.
    [3]OHARA H, OKAZAKI K, TSUBOUCHI H, et al.Clinical diagnostic criteria of Ig G4-related sclerosing cholangitis 2012[J].J Hepatobiliary Pancreat Sci, 2012, 19 (5) :536-542.
    [4]NAKAZAWA T, NAITOH I, OHARA T, et al.Diagnostic criteria for Ig G4-related sclerosing cholangitis based on cholangiographic classification[J].J Gastroenterol, 2012, 47 (1) :79-87.
    [5]KAMISAWA T, FUNATA, HAYASHI Y, et al.Lymphoplasmacytic sclerosing pancreatitis is a pancreatic lesion of Ig G4-related systemic[J].Am J Surg Pathol, 2004, 28 (8) :1114.
    [6]MARTINEZ-VALLE F, FEMANDEZ-CODINA A, PINAL-FEMANDEZ L, et al.Ig G4-related disease:Evidence from six recent cohorts[J].Autoimmun Rev, 2017, 16 (2) :168-172.
    [7]BJOENSSON E, CHARI ST, SMYRK TC, et al.Immunoglobulin G4 associated cholangitis:Description of an emerging clinical entity based on review of the literature[J].Hepatology, 2007, 45 (6) :1547-1554.
    [8]NAKAZAWA T, IKEDA Y, KAWAGUCHI Y, et al.Isolated intrapancreatic Ig G4-related sclerosing cholangitis[J].World J Gastroenterol, 2015, 21 (4) :1334-1343.
    [9]ATSUSHI K, ICHIRO T, ISAO N, et al.Nationwide epidemiological survey of autoimmune[J].Pancreas, 2015, 44 (4) :535-539.
    [10]INOUE D, YOSHIDA K, YONEDA N, et al.Ig G4-related disease:dataset of 235 consecutive patients[J].Medicine (Baltimore) , 2015, 94 (15) :e680.
    [11]ZEN Y, KAWAKAMI H, KIM JH, et al.Ig G4-related sclerosing cholangitis:all we need to know[J].J Gastroenterol, 2016, 51 (4) :295-312.
    [12]ZEN Y, FUJII T, HARADA K, et al.Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis[J].Hepatology, 2007, 45 (6) :1538-1546.
    [13]MIYOSHI H, UCHIDA K, TANIGUCHI T, et al.Circulating na6ve and CD4+CD25high regulatory T cells in patients with autoimmune pancreatitis[J].Pancreas, 2008, 36 (2) :133-140.
    [14]CARRUTHERS MN, KHOSROSHAHI A, AUGUSTIN T, et al.The diagnostic utility of serum Ig G4 concentrations in Ig G4-related disease[J].Ann Rheum Dis, 2015, 74 (1) :14-18.
    [15]BOONSTRA K, CULVER EL, POEN AC, et al.Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis[J].Hepatology, 2014, 59 (5) :1954-1963.
    [16]CULVER EL, SADLER R, SIMPSON D, et al.Elevated serum Ig G4 levels in diagnosis, treatment response, organ involvement, and relapse in a prospective Ig G4-related disease UK cohort[J].Am J Gastroenterol, 2016, 111 (5) :733-743.
    [17]GHAZALE A, CHARI ST, ZHANG L, et al.Immunoglobulin G4-associated cholangitis:clinical profile and response to therapy[J].Gastroenterology, 2008, 134 (3) :706-715.
    [18]MASAMUNE A, NISHIMORI I, KIKUTA K, et al.Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis[J].Gut, 2017, 66 (3) :487-494.
    [19]YOU MW, KIM JH, BYUN JH, et al.Relapse of Ig G4-related sclerosing cholangitis after steroid therapy:Image findings and risk factors[J].Eur Radiol, 2014, 24 (5) :1039-1048.
    [20]CARRUTHERS MN, TOPAZIAN MD, KHOSROSHAHI A, et al.Rituximab for Ig G4-related disease:A prospective, open-label trial[J].Ann Rheum Dis, 2015, 74 (6) :1171-1177.
    [21]KHOSROSHAHI A, BLOCH DB, DESHPANDE V, et al.Rituximab therapy leads to rapid decline of serum Ig G4 levels and prompt clinical improvement in Ig G4-related systemic disease[J].Arthritis Rheum, 2010, 62 (6) :1755-1762.
    [22]KHOSROSHAHI A, CARRUTHERS MN, DESHPANDE V, et al.Rituximab for the treatment of Ig G4-related disease:Lessons from10 consecutive patients[J].Medicine (Baltimore) , 2012, 91 (1) :57-66.
    [23]MURAKAMI J, MATSUI S, ISHIZAWA S, et al.Recurrence of Ig G4-related disease following treatment with rituximab[J].Mod Rheumatol, 2013, 23 (6) :1226-1230.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1986) PDF downloads(389) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return